scholarly journals Recombinant human parathyroid hormone in the therapy of hypoparathyroidism

2017 ◽  
Vol 89 (10) ◽  
pp. 80-86 ◽  
Author(s):  
A K Eremkina ◽  
N G Mokrysheva ◽  
E V Kovaleva ◽  
Yu A Krupinova
Keyword(s):  
Parathyroid Hormone ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Normal Serum ◽  
Biologically Active ◽  
Vitamin D Metabolites ◽  
Treatment Regimens ◽  
Normal Serum Calcium ◽  
Pathogenetic Therapy ◽  
Dosing Regimens

Hypoparathyroidism is an endocrine disease that results from deficiency or complete absence of parathyroid hormone (PTH), a biologically active 84-amino acid polypeptide. Standard therapy for chronic hypoparathyroidism includes oral calcium salts and active vitamin D metabolites and is aimed at maintaining a balance between optimal near-normal serum calcium concentration and normocalcuria. Traditional treatment regimens not always lead to the compensation for calcium and phosphorus metabolism. Until recently, hypoparathyroidism is the only endocrine disorder that has not been treated with the recombinant hormone. To date, two recombinant PTH forms have been synthesized, which can be used as pathogenetic therapy for hypoparathyroidism. This review is dedicated to replacement therapy for hypoparathyroidism, by using both the full-length PTH molecule (1—84) and its shorter, but fully active, PTH form (1—34). This review considers stages in the developmental of hormone replacement therapy for hypoparathyroidism, discusses the most rational dosing regimens, and compares their efficacy and safety, as well as prospects for the development of this area.

Optimizing continuous-combined hormone replacement therapy for postmenopausal women: A comparison of six different treatment regimens

2000 ◽  
Vol 182 (3) ◽  
pp. 560-567 ◽  
Author(s):  
Jorma E. Heikkinen ◽  
Raija T. Vaheri ◽  
Satu M. Ahomäki ◽  
Petri M.T. Kainulainen ◽  
Antti T. Viitanen ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Treatment Regimens

Primary hyperparathyroidism

2018 ◽  
Author(s):  
John Newell-Price ◽  
Alia Munir ◽  
Miguel Debono
Keyword(s):  
Parathyroid Hormone ◽  
Primary Hyperparathyroidism ◽  
Bone Mineralization ◽  
Hormone Secretion ◽  
Normal Serum ◽  
Renal Physiology ◽  
Calcium Sensing ◽  
Inhibitory Feedback ◽  
Normal Serum Calcium ◽  
Solitary Adenoma

Primary hyperparathyroidism is a disorder of bone mineralization and renal physiology due to excess parathyroid hormone secretion. Parathyroid hormone (PTH) is produced and released by the parathyroid chief cells, under regulation of the G- protein-coupled calcium-sensing receptor. Primary hyperparathyroidism occurs when there is a loss of the inhibitory feedback of PTH release by extracellular calcium. The rise in PTH levels is initially associated with a normal serum calcium, and then over time with hypercalcaemia. The most common cause of primary hyperparathyroidism is a benign solitary adenoma (80%). Other causes include multiple adenomas and hyperplasia. This chapter reviews the causes, clinical features, and management of primary hyperparathyroidism.

Bio-identical hormones replacement therapy and the quality of life for breast cancer patients.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 87-87
Author(s):  
TS Wiley
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Replacement Therapy ◽  
Clinical Symptoms ◽  
Hormone Replacement ◽  
Well Being ◽  
Normal Serum ◽  
Breast Cancer Patients ◽  
The Impact

87 Background: Many treatments for breast cancer block the estrogen receptor or the androgen conversion of estrogen to reduce the risk of relapse. This results in a change in the hormonal milieu. Although most women tolerate the change in hormonal status, problems can arise from this change. Without estrogen, clinical symptoms include hot flashes, sleeplessness, insulin sensitivity, and mood changes. Here, it is examined that the use of estrogen and progesterone bio-identical hormone replacement therapy (BHRT) for women in the normal physiological pattern of reproductive women is expected to coincide with increased well-being and better quality of life for women with breast cancer. Methods: This BHRT approach uses bio-identical estrogen and progesterone to restore the woman’s body to normal serum levels through twice daily transdermal application. Using real “bio-identical” or plant-derived human molecular hormones compounded via a standard formula, concentration, and packaging of transdermal creams (Estradiol E2) of 1 mg/0.1ml and progesterone P4 of 20 mg/0.1 ml). Furthermore, through an understanding of hormonal mechanisms, this BHRT mimics the female reproductive cycle by following a 28 day cycle. Results: Throughout the study, women were asked to how gauge their general well-being and quality of life. Most women reported resolution of menopausal symptoms, better sleep, decreased migraines and incontinence, increased focus, and increased libido. Most patients were pleased to be on the treatment and showed general improvement in the quality of life. Conclusions: We present the general mechanisms of action for BHRT and explain clinical trials conducted over the past decade have been examining the impact on the overall well-being and quality of life for 112 patients, as well as the impact on various cancers as well as other chronic conditions. Patients reported increased energy and overall well-being. BHRT provided resolution of most all of the patients subjective anti-estrogenic complaints. It is also observed that the recurrence rate of various breast cancers was no higher than national averages. Therefore, BHRT and rhythmic dosing seems to greatly improve well-being with no increase of cancer risk.

Parathyroid Hormone(1–84) Treatment of Postmenopausal Women with Low Bone Mass Receiving Hormone Replacement Therapy

2008 ◽  
Vol 83 (2) ◽  
pp. 85-92 ◽  
Author(s):  
I. Fogelman ◽  
J. N. Fordham ◽  
W. D. Fraser ◽  
T. D. Spector ◽  
C. Christiansen ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Hormone Replacement Therapy ◽  
Bone Mass ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Hormone Replacement ◽  
Low Bone Mass

scholarly journals Self-adjusted postmenopausal hormone replacement therapy: effects on the biological and immunological profile of FSH and correlation to climacteric symptoms

2002 ◽  
pp. 333-338 ◽  
Author(s):  
T Vihtamaki ◽  
M Simoni ◽  
R Tuimala ◽  
E Nieschlag ◽  
KK Vihko
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Serum Levels ◽  
Cell System ◽  
Biologically Active ◽  
Sex Hormone Binding Globulin ◽  
Poor Correlation ◽  
Positive Correlation ◽  
Specific Scheme

OBJECTIVE: The purpose of the present study was to evaluate the hormonal profile of patients of postmenopausal age during estrogen replacement therapy (ERT) with special reference to the serum levels of biologically active FSH (B-FSH) in a self-adjusted ERT model. DESIGN: The hormonal values found have been correlated to climateric symptoms reported by the patients (scored by the Kupperman menopausal index (KI)). METHODS: B-FSH was measured using an assay based on a cell system transfected permanently with FSH receptor cDNA. All women (n=32) applied estradiol percutaneously using 1 mg estradiol-17beta (E(2)) as an initial dose and were encouraged to increase the daily dose until they felt comfortable according to a specific scheme. Twelve of the 32 women were hysterectomized and treated, accordingly, with ERT only; 20 women received megestrol acetate monthly for 10 days. RESULTS: The initial average KI was 30 (range 10-54). A high degree of correlation (r=0.83; P<0.001) was observed between B-FSH and immunologically active FSH (I-FSH). Serum I-FSH and E(2) correlated negatively (r=-0.21; P<0.001); similarly, a negative correlation (r=-0.15; P<0.01) was observed between serum B-FSH and E(2) levels. Serum I-FSH and KI showed modest but significant positive correlation (r=0.13; P<0.01); a somewhat higher degree of correlation (r=0.19; P<0.005) was observed when B-FSH and KI were compared. E(2) showed positive correlation to serum sex-hormone binding globulin levels (r=0.22; P<0.001). CONCLUSIONS: This study shows that the transdermal self-adjusted hormone replacement therapy (HRT) model introduced is suitable for studies on endocrine changes during postmenopausal ERT. The finding of poor correlation between serum E(2) levels and KI emphasizes the importance of hormonal measurements during postmenopausal HRT.

Sign in / Sign up

Export Citation Format

Share Document